PBGH in the News
Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven
The Pacific Business Group on Health created a narrow network of high-quality providers that its member employers contract with directly […]
Health Lobbyist Spent $75 Million to Kill Surprise Medical Bills Reform
“A health lobby group reportedly spent tens of millions of dollars in a campaign to influence legislation aimed at ending […]
PBGH CEO discusses the landmark Sutter Health lawsuit on 60 Minutes
Hospital consolidation is one of the main reasons the cost of health care in this country is going through the roof.
With Freezers in Tow, U.S. Employers Rush to Fill Vaccine Void
Most employers say they’ll strongly encourage the COVID-19 vaccines but not require them.
Planning for COVID Vaccines and Costs
COVID-19 drugs and therapeutics were developed with significant federal investment; that should be reflected in their pricing.
3 Reasons Employers Should Be Concerned About ACA Repeal
Employers have concerns surrounding the legal challenge to the Affordable Care Act (ACA).
PBGH issues statement on Xavier Becerra HHS nomination
On December 7, 2020, the Pacific Business Group on Health (PBGH) issued this statement regarding the announcement that President-elect Biden will nominate California Attorney General Xavier Becerra to serve as Secretary of the U.S. Department of Health and Human Services (HHS).
New Trump administration rule directs insurers to reveal what they pay for prescriptions
“There’s a limit to what transparency can do,” said Shawn Gremminger, health policy director at the Pacific Business Group on Health, which represents large self-insured employers. “That’s why we’re increasingly comfortable with policies that get at the underlying prices of drugs.” As an example, he cited the Trump administration’s proposal to tie what Medicare pays for drugs to lower prices in other countries.
US needs price controls for COVID-19 drugs, employer advocacy group says
The Employers’ Prescription for Affordable Drugs said Medicare should determine fair prices for COVID-19 drugs and vaccines and pointed to Gilead’s remdesivir as an example of an overpriced drug. The FDA approved remdesivir as a COVID-19 treatment in October. The drug costs private health plans more than $3,00 per treatment course, Bloomberg reported.
Private employers show new interest in expanded Medicare and regulated drug prices
“There is a significant difference in what employers are prepared to support,” said Elizabeth Mitchell, president of the Pacific Business Group on Health, a consortium of large companies including Boeing, Safeway, Walmart and Wells Fargo.
